Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-02-14
2006-02-14
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S372000
Reexamination Certificate
active
06998403
ABSTRACT:
A compound of formula (I):wherein:R1and R2together form a benzo ring optionally substituted by halogen or by alkyl, alkoxy, cyano, nitro, hydroxy, amino, alkylamino, dialkylamino or trifluoromethyl, and R3and R4represent hydrogen,orR1and R4represent hydrogen and R2and R3together form a benzo ring optionally substituted by halogen or by alkyl, alkoxy, cyano, nitro, hydroxy, amino, alkylamino, dialkylamino or trifluoromethyl,orR1and R2represent hydrogen and R3and R4together form a benzo ring optionally substituted by halogen or by alkyl, alkoxy, cyano, nitro, hydroxy, amino, alkylamino, dialkylamino or trifluoromethyl,addition salts thereof with a pharmaceutically acceptable acid or base, andmethods of treating conditions susceptible to α2-AR/5-HT2Cantagonists.
REFERENCES:
patent: 2002/0025965 (2002-02-01), Lavielle et al.
patent: 1170288 (2002-01-01), None
Gaster et al. Annual Reports in Medicinal Chemistry, vol. 33, p. 21-30 (1998).
Brefel-Courbon et al. Drug Therapy 10, pp. 189-207 (1998).
Hoffman in Basic & Clinical Pharmacology (6thed.) edited by Bertram G. Katzung, pp. 132-136 (1995).
Invernizzi, et al.,Prog. Neuropsychophamacol. Bio. Psychiatry, 2004, 28, 819-827.
Millan, et al.,J. Psychopharmacol., 2000, 14, 114-138.
Di Matteo, et al.,Trends Pharmacol. Sci., 2001, 22, 229-232.
Done, et al.,Neuropharmacology, 1994, 33, 411-421.
O'Neill, et al.,Pharmacology, Biochemistry and Behavior, 1999, 63, 237-243.
Reavill, et al.,British Journal of Psychopharmacology, 1999, 126, 572-574.
Herrick-Davis, et al.,Journal of Pharmacology and Experimental Therapeutics, 2000, 295, 226-232.
Wood, et al.,Drug Development Research, 2001, 54, 88-94.
Paiva, et al.,Psychopharmacology, 1988, 96, 395-399.
Dugovic,Journal Sleep Research, 1992, 1, 1163-1168.
Landolt, et al.,Neuropsychopharmacology, 1999, 21, 455-466.
Sharpley, et al.,Biological Psychiatry, 2000, 47, 468-470.
Foreman, et al.,Life Sciences, 1989, 45, 1263-1270.
Klint, et al.,Psychopharmacology, 1995, 119, 291-294.
Hirschfeld,Journal of Clinical Psychiatry, 60 Suppl. 17:32-35, 1999.
Popova, et al.,Neuroendocrinology, 2002, 76, 28-34.
McMahon, et al.,Journal of Neuroscience, 2001, 21, 7781-7787.
Filip, et al.,Pharmacology, Biochemistry and Behaviour, 2002, 71, 545-756.
Fox, et al.,Drug News and Perspectives, 1999, 12:477-483.
Fox, et al.,Movement Disorders, 2000, 15:1064-1069.
Sara, et al.,Behavioural Neural Biology, 1989, 51, 401-411.
Smith, et al.,Journal of Psychopharmacology, 1992, 6, 376-381.
Coull, et al.,Psychopharmacology, 1996, 123, 239-249.
Tellez, et al.,European Journal of Pharmacology, 1995, 277, 113-116.
Haapalinna, et al.,European Journal of Pharmacology, 1998, 347, 29-40.
“Dexefaroxan, efaroxan, L-0046, RX-821037”,Pharmaproject, Phase II Clinical Trial (2005).
Nutt,J. Psychopharmacology, 1994, 8, 193-195.
Litman, et al.,British Journal of Psychiatry, 1996, 168, 571-579.
Hertel, et al.,Science, 1999, 286, 105-107.
“Idazoxan, CGP-25811A, L0022, RX-781094”,Pharmaproject, Phase II Clinical Trial (2005).
“Fipamezol, JP-1730”,Pharmaproject, Phase II Clinical Trial (2005).
Grondin, et al.,Naunyn Schmiedebergs Archives of Pharmacology, 2000, Feb:361, 181-186.
Rascol, et al.,Mov. Disord., 2001, 16, 708-713.
Brown, et al.,Investigational Drugs, 2002, 5, 454-468.
Clark, et al.,Neuroendocrinology, 1985, 41, 36-43.
Reid, et al.,Lancet, 1987, 22, (8556):421-423.
Koskinen, et al.,Physiology and Behaviour, 1991, 50, 589-593.
Kunelius, et al.,Urology, 1997, 49, 441-444.
Di Cara Benjamin
Gobert Alain
Lavielle Gilbert
Millan Mark
Muller Olivier
Bernhardt Emily
Hueschen and Sage
Les Laboratoires Servier
LandOfFree
Benzoindoline compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Benzoindoline compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzoindoline compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3652517